Molecular Infectious Disease Testing Market Research Report, Size, Share, Analysis, Growth by Forecast to 2031
Global Molecular Infectious Disease
Testing Market Overview
The global molecular
infectious disease testing market is projected to grow at a compound
annual growth rate (CAGR) of approximately 13% over the next five years. This
expansion is driven by the increasing global burden of infectious diseases,
rising demand for rapid and accurate diagnostic results, technological
advancements in molecular diagnostics, and growing investments in research
& development (R&D) and public health infrastructure.
Download Sample PDF Copy: https://meditechinsights.com/molecular-infectious-disease-testing-market/request-sample/
Molecular infectious disease testing encompasses
advanced diagnostic techniques used to detect and characterize
pathogens—including viruses, bacteria, and other microorganisms—based on their
genetic material. These methods commonly utilize polymerase chain reaction
(PCR), isothermal amplification technologies, and next-generation sequencing
(NGS), among others, to deliver high sensitivity and specificity.
By leveraging these molecular approaches, clinicians
can accurately identify causative pathogens, differentiate between viral and
bacterial infections, detect co-infections, and guide appropriate antimicrobial
therapy. Molecular diagnostics also enable early disease detection—often before
severe symptoms develop—supporting timely clinical intervention and improved
patient outcomes.
Rising
Burden of Infectious Diseases Driving Market Growth
A primary factor fueling market expansion is the
escalating global prevalence of infectious diseases. Healthcare systems
worldwide are under increasing pressure to detect, manage, and contain
infections rapidly and accurately.
Infectious diseases remain a leading cause of global
morbidity and mortality. In 2024:
- Tuberculosis accounted for 10.7 million cases and 1.23 million
deaths.
- Malaria recorded 282 million cases (a 3% increase from 2023) and
610,000 deaths.
- Dengue cases surged dramatically from 505,430 in 2000 to 14.6
million in 2024.
(Source: WHO)
Multiple structural factors—including urbanization,
globalization, climate change, antimicrobial resistance (AMR), and aging
populations—are contributing to rising incidences of respiratory infections,
sexually transmitted infections (STIs), gastrointestinal diseases,
tuberculosis, hepatitis, HIV, and vector-borne diseases. Furthermore, the
emergence and re-emergence of novel pathogens continue to increase the
frequency and complexity of outbreaks.
Molecular diagnostics directly address these challenges
by enabling early, precise detection of pathogens—even at low concentrations
and prior to widespread transmission. As disease complexity increases,
clinicians and public health authorities increasingly rely on molecular tests
for accurate differentiation of pathogens, identification of co-infections, and
selection of targeted therapies.
Delayed or inaccurate diagnosis significantly increases
healthcare costs due to prolonged hospital stays and inappropriate treatment.
Molecular testing helps reduce this financial burden by enabling faster treatment
decisions, improving antimicrobial stewardship, and shortening hospitalization
durations.
From a public health perspective, molecular testing
also enhances disease surveillance. These tests support rapid outbreak
detection, large-scale screening programs, and tracking of pathogen mutations
and transmission patterns. Consequently, governments and global health
organizations continue to invest in strengthening molecular diagnostic
capabilities as a core component of outbreak preparedness.
As post-pandemic awareness grows, demand for routine
screening and expectations for fast, laboratory-grade accuracy are expected to
further accelerate long-term market growth.
Download Sample PDF Copy: https://meditechinsights.com/molecular-infectious-disease-testing-market/request-sample/
Growth
in Point-of-Care (POC) Molecular Solutions: A Key Opportunity
Point-of-care (POC) molecular diagnostics represent one
of the most significant growth opportunities in the market. Unlike traditional
centralized laboratory testing, POC molecular platforms deliver
laboratory-level sensitivity and specificity at or near the site of patient
care.
Healthcare settings such as emergency departments,
outpatient clinics, and primary care facilities increasingly require rapid
diagnostic solutions. POC molecular tests provide actionable results within
minutes to an hour, enabling same-visit treatment decisions. This capability is
particularly valuable for respiratory infections, sexually transmitted
infections, and hospital-acquired infections, where delays in diagnosis can
worsen outcomes and increase transmission risk.
POC molecular systems also expand access to
high-quality diagnostics in decentralized and resource-limited settings,
including rural clinics and community health programs. Compact, automated
platforms with minimal sample preparation requirements allow reliable testing
even where centralized laboratories are unavailable.
From a public health standpoint, rapid on-site testing
enhances outbreak control by enabling early case identification, timely
isolation decisions, and prompt treatment initiation. As a result, governments
and health agencies are promoting POC molecular diagnostics as essential tools
for epidemic preparedness and routine surveillance.
For manufacturers, POC platforms create recurring
revenue opportunities through consumables and cartridge-based systems. Ongoing
technological advancements are reducing costs, improving ease of use, and
expanding multiplex capabilities—positioning POC molecular testing as a major
growth engine in the global market.
Strategic
Growth Initiatives by Market Players
Market participants are adopting various
strategies—including product launches, strategic alliances, and acquisitions—to
strengthen their competitive positions.
- In October 2025, Sysmex entered a strategic alliance with QIAGEN for
the exclusive distribution of molecular diagnostic instruments and
reagents for infectious diseases and oncology in Japan, expanding access
to tuberculosis diagnostics and other molecular tests.
- In June 2025, bioMérieux acquired the assets of Day Zero Diagnostics
to enhance its next-generation sequencing (NGS) capabilities in infectious
disease diagnostics and antimicrobial resistance detection.
- In February 2023, Thermo Fisher Scientific launched Applied
Biosystems TaqPath real-time PCR kits in India for the detection of TB,
HIV, HBV, and HCV, strengthening the country’s molecular diagnostics
ecosystem.
These initiatives reflect a broader industry trend
toward innovation, portfolio expansion, and geographic penetration.
Product
and Service Segment Outlook
Reagents and kits represent the largest revenue segment
in the molecular infectious disease testing market. Their dominance stems from
routine, high-volume testing requirements across hospitals and diagnostic
laboratories. Unlike instruments—which typically involve one-time capital purchases—reagents,
primer sets, probes, and assay kits generate recurring revenue based on testing
volume.
Services and software are the fastest-growing segments,
driven by increasing adoption of advanced data analytics, bioinformatics
solutions, laboratory automation, and connectivity platforms. Growth is further
supported by the rising use of multiplex assays, NGS technologies, and the need
for integrated workflow management and regulatory-compliant reporting systems.
Regional
Outlook
North America is expected to maintain the largest share
of the molecular infectious disease testing market. The region benefits from:
- Advanced healthcare infrastructure
- Strong reimbursement frameworks
- High testing volumes
- Robust public health programs
- Significant R&D investments
- Presence of leading molecular diagnostic companies
Asia Pacific (APAC) is projected to be the
fastest-growing region. Market growth in APAC is driven by a large patient
population, increasing infectious disease burden, expanding healthcare infrastructure,
rising government investment in diagnostics, rapid urbanization, and growing
local manufacturing initiatives.
Browse
Research Report: https://meditechinsights.com/molecular-infectious-disease-testing-market/
Competitive
Landscape
The global molecular infectious disease testing market
includes both established leaders and emerging players, such as:
- Danaher Corporation
- F. Hoffmann-La Roche Ltd
- bioMérieux
- Abbott
- Thermo Fisher Scientific Inc.
- QIAGEN
- Hologic, Inc.
- Becton, Dickinson and Company (BD)
- Siemens Healthineers AG
- Seegene Inc.
Global Molecular Infectious Disease Testing Market
Segmentation
This report by Medi-Tech Insights provides the size
of the global molecular infectious disease testing market at the regional-
and country-level from 2024 to 2031. The report further segments the market
based on product and service, type, technology, application, and end user.
Market Size & Forecast (2024-2031), By
Product and Service, USD Billion
·
Reagents and Kits
·
Instruments
·
Services and Software
Market Size & Forecast (2024-2031), By
Type, USD Billion
·
Singleplex Testing
·
Multiplex Testing
Market Size & Forecast (2024-2031), By
Technology, USD Billion
·
Polymerase Chain Reaction (PCR)
·
Isothermal Nucleic Acid Amplification
·
DNA Sequencing and Next-generation
Sequencing (NGS)
·
In Situ Hybridization
·
DNA Microarrays
·
Other Technologies
Market Size & Forecast (2024-2031), By
Application, USD Billion
·
Respiratory Infectious Diseases
·
Gastrointestinal Infectious Diseases
·
Sexually Transmitted Infections (STIs)
·
Vector-borne Diseases
·
Hospital-acquired Infections
·
Other Applications
Market Size & Forecast (2024-2031), By
End User, USD Billion
·
Diagnostic Laboratories
·
Hospitals and Clinics
·
Other End Users
Market Size & Forecast (2024-2031), By
Region, USD Billion
·
North America
o US
o Canada
·
Europe
o UK
o Germany
o France
o Italy
o Spain
o Rest of Europe
·
Asia Pacific
o China
o India
o Japan
o Rest of Asia Pacific
·
Latin America
·
Middle East & Africa
Related Reports:
About Medi-Tech Insights;
Medi-Tech Insights is a healthcare-focused business research &
insights firm. Our clients include Fortune 500 companies, blue-chip investors
& hyper-growth start-ups. We have completed 100+ projects in Digital
Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research
combined with deep-dive interviews with industry-leading CXO, VPs, and key
demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
Comments
Post a Comment